This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Use of Fixed-Dose Combination Therapy

Murray Epstein, MD; George Bakris, MD

Arch Intern Med. 1996;156(17):1969-1978.

Abstract
Despite the availability of many newer antihypertensive agents, hypertensive patients remain at higher risk of premature death than the general population. This persistence of morbidity and mortality may be accounted for by the frequent failure to achieve adequate blood pressure reduction despite an extensive array of available antihypertensive agents. Such considerations have led to reassessment of the potential role of fixed-dose combination agents in the antihypertensive armamentarium. The rationale for combination therapy relates to the concept that antihypertensive efficacy may be enhanced when 2 classes of agents are combined. In addition, combination therapy enhances tolerability—1 drug of a fixed combination can antagonize some of the adverse effects of the second drug. Fixed-dose combination therapy simplifies the treatment regimen, preventing treatment failures that might result from missed doses. An additional novel concept is the possibility of enhancing salutary effects on target organs, including regressing left ventricular hypertension and retarding progression of renal disease, by combination therapy over and above the effects expected from the fall in arterial pressure alone. The recent approval by the Food and Drug Administration of 2 fixed-dose angiotensin-converting enzyme inhibitor/calcium antagonist combinations has focused attention on and prompted reexamination of this issue.

Arch Intern Med. 1996;156:1969-1978

Author Affiliations
From the Division of Nephrology, Department of Medicine, Department of Veterans Affairs Medical Center and University of Miami School of Medicine, Miami, Fla (Dr Epstein); and Departments of Preventive and Internal Medicine, Rush University Hypertension Center, Rush-Presbyterian—St Luke's Medical Center, Chicago, Ill (Dr Bakris).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combination-drug products: Benefit or burden to patients?
Bucci and Possidente
Am J Health Syst Pharm 2006;63:1654-1655.
FULL TEXT  

Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients
Nathan et al.
Hypertension 2005;46:637-642.
ABSTRACT | FULL TEXT  

Efficacy of Extended-Release Niacin With Lovastatin for Hypercholesterolemia: Assessing All Reasonable Doses With Innovative Surface Graph Analysis
Insull et al.
Arch Intern Med 2004;164:1121-1127.
ABSTRACT | FULL TEXT  

Hypertension and the Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2004;38:103-119.
ABSTRACT  

The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco et al.
Diabetes Care 2002;25:134-147.
FULL TEXT  

Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension
Naidu et al.
Postgrad. Med. J. 2000;76:350-353.
ABSTRACT | FULL TEXT  

Fixed Low-Dose Drug Combination for the Treatment of Hypertension
Chrysant
Arch Fam Med 1998;7:370-376.
ABSTRACT | FULL TEXT  

The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Arch Intern Med 1997;157:2413-2446.
ABSTRACT  

A 42-Year-Old Man With Hypertension
Oparil
JAMA 1997;278:1015-1021.
ABSTRACT  

History of Fixed-Dose Combination Therapy for Hypertension
Wofford
Arch Intern Med 1997;157:1044-1044.
ABSTRACT  

Hypertension Treatment: Its Past and (Perhaps) Its Future
Dustan
Arch Intern Med 1996;156:1913-1914.
ABSTRACT